Indeed, it has been observed that many enzymes involved in the de novo cholesterol biosynthesis are deregulated in cancer cells, especially 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMGCR), the rate-limiting enzyme of the entire biosynthesis process [75,76]. The gene discussed is HMGCR; the disease is cancer.